Allarity Therapeutics Inc (ALLR) 시세

If I was a Market Maker, I would do to this stock what has been DONE to it this last week. Attempt to break the confidence of everyone connected with the company so cheaper shares could be accumulated.

CHEAPER SHARES?!!!!!!!!!!!!!!!!!!!

Sure. Market Makers KNOW that companies like ATTR who are devoting their time and talent to helping cure people of cancerous issues are WORTH far more than any AI stock you can buy right now.

Watch disgruntled AI chip investors TURN to a sector that is trying to extend the quality of life for humanity. ALLR fits the bill for me.

peeps were expecting news yesterday besides the settlement

$ALLR only has a market cap of around $6 million with a drug in Phase 2 clinical trials. It should be trading at $20 per share right now. Oh well it looks like I will be adding. No one ever said the stock market was efficient.

ALLR...$1.23...Bouncing off the $1.12 dip...🥳

Well, this is fantastic.

grabbed some 1.17's on dip heading into the data release.

Wtf?

ALLR...$1.36...🥳 ... https://www.globenewswire.com/news-release/2025/01/30/3017967/0/en/Allarity-Therapeutics-Announces-Filing-of-Form-8-K-Regarding-Settlement-Agreement-in-Principle-with-SEC.html

looked like a low volume stop-loss sweep, imo
could get really interesting this afternoon
$ALLR

Wtf?

RNAZ flying today with little more than speculation. Has more shares outstanding than ALLR and no assurance it has medicine any better than ALLR's ... far as anyone is sharing right now.

I'm looking for ALLR to start climbing near the close today and maybe higher in A/H.s. Tomorrow morning should get a lot of generous upside going into the mid-afternoon if all goes well.

Added to the treasure chest some of those $1.49's.

$ALLR presenting tomorrow approx 2:15 pm
Fasten your seatbelts

I need toi follow your alerts.

Good call.

Maybe we might test next resistance level at $2.25

Ruff Ruff...🥳...Hit $1.99 of my $1 Alert...

nice little pop riding the rest after taking profits gl

Their all dogs until their not... Well I bought this dog at $1 and it hit $1.72...🥳...

ALLR is a dog.

company has great products, still being tested, but has no value. It is worth minus $11M. Looks like a P&D.

1.70 up

ALLR...$1.62...Off my $1 Alert...🥳

georgie18

Member Level
Re: georgie18 post# 672254

Friday, January 24, 2025 9:53:30 AM

Post#
672296
of 672488
ALLR...$1.46...Off my $1 Alert...🥳Looking for Double Top Break here...

georgie18

Member Level
Re: georgie18 post# 388997

Friday, January 24, 2025 7:28:59 AM

Post#
389007
of 389045
ALLR...$133s clearing here...🥳

georgie18

Member Level
Re: georgie18 post# 672217

Thursday, January 23, 2025 7:14:06 PM

Post#
672237
of 672252
ALLR...$1.28s hitting here...🥳...Bullish Engulfing Candle on todays close....

georgie18

Member Level
Re: georgie18 post# 388353

Thursday, January 23, 2025 3:52:10 PM

Post#
388987
of 388996
ALLR...$1.25...Hit $1.50...HOD...🥳
georgie18

Member Level
Re: georgie18 post# 671010

Friday, January 10, 2025 1:13:53 PM

Post#
671057
of 672215
ALLR...$1.13s clearing here...🥳

georgie18

Member Level
Re: None

Friday, January 10, 2025 9:35:44 AM

Post#
470
of 470
ALLR...$1...🥳...scaling in here...

trying for those 1.60's again

$ALLR Finally some clarity on the true value of ALLR coming this week, the chart is primed, the officers filed a huge number of insider shares, if the results continue to be positive ALLR can go to $10-20 quickly.

http://ddr-inhibitors-summit.com/speaker/thomas-jensen/

https://clinicaltrials.gov/search?term=2x-121&viewType=Table

https://www.nasdaq.com/market-activity/stocks/allr/sec-filings

Yep - got a winner here.

ALLR...$1.46...Off my $1 Alert...🥳Looking for Double Top Break here...

georgie18

Member Level
Re: georgie18 post# 388997

Friday, January 24, 2025 7:28:59 AM

Post#
389007
of 389045
ALLR...$133s clearing here...🥳

georgie18

Member Level
Re: georgie18 post# 672217

Thursday, January 23, 2025 7:14:06 PM

Post#
672237
of 672252
ALLR...$1.28s hitting here...🥳...Bullish Engulfing Candle on todays close....

georgie18

Member Level
Re: georgie18 post# 388353

Thursday, January 23, 2025 3:52:10 PM

Post#
388987
of 388996
ALLR...$1.25...Hit $1.50...HOD...🥳
georgie18

Member Level
Re: georgie18 post# 671010

Friday, January 10, 2025 1:13:53 PM

Post#
671057
of 672215
ALLR...$1.13s clearing here...🥳

georgie18

Member Level
Re: None

Friday, January 10, 2025 9:35:44 AM

Post#
470
of 470
ALLR...$1...🥳...scaling in here...

ALLR...$133s clearing here...🥳

georgie18

Member Level
Re: georgie18 post# 672217

Thursday, January 23, 2025 7:14:06 PM

Post#
672237
of 672252
ALLR...$1.28s hitting here...🥳...Bullish Engulfing Candle on todays close....

georgie18

Member Level
Re: georgie18 post# 388353

Thursday, January 23, 2025 3:52:10 PM

Post#
388987
of 388996
ALLR...$1.25...Hit $1.50...HOD...🥳
georgie18

Member Level
Re: georgie18 post# 671010

Friday, January 10, 2025 1:13:53 PM

Post#
671057
of 672215
ALLR...$1.13s clearing here...🥳

georgie18

Member Level
Re: None

Friday, January 10, 2025 9:35:44 AM

Post#
470
of 470
ALLR...$1...🥳...scaling in here...

ACON liftoff

ALLR Live the dream brothers RNAZ Cure to cancer

ALLR...$1.28s hitting here...🥳...Bullish Engulfing Candle on todays close....

georgie18

Member Level
Re: georgie18 post# 388353

Thursday, January 23, 2025 3:52:10 PM

Post#
388987
of 388996
ALLR...$1.25...Hit $1.50...HOD...🥳
georgie18

Member Level
Re: georgie18 post# 671010

Friday, January 10, 2025 1:13:53 PM

Post#
671057
of 672215
ALLR...$1.13s clearing here...🥳

georgie18

Member Level
Re: None

Friday, January 10, 2025 9:35:44 AM

Post#
470
of 470
ALLR...$1...🥳...scaling in here...

ALLR...$1.25...Hit $1.50...HOD...🥳Off my $1 Alert...

georgie18

Member Level
Re: georgie18 post# 671010

Friday, January 10, 2025 1:13:53 PM

Post#
671057
of 672215
ALLR...$1.13s clearing here...🥳

georgie18

Member Level
Re: None

Friday, January 10, 2025 9:35:44 AM

Post#
470
of 470
ALLR...$1...🥳...scaling in here...

ALLR, 10 day hourly

ALLR...$1.13s clearing here...🥳

georgie18

Member Level
Re: None

Friday, January 10, 2025 9:35:44 AM

Post#
470
of 470
ALLR...$1...🥳...scaling in here...

ALLR...$1...🥳...scaling in here...

Yes but this had a long Inverted Hammer candle at the close this should continue to move upwards. Also ALLR is making higher lows and higher highs. 📈

turd back down 

Big volume breakout on ALLR.

Yes ALLR was due for a breakout. $1.34 is next resistance then this could really fly.

$1.30s

Hmmm, lots of eyes here the morn.

Volume uptick due to company PR...

ALLR, new 52 week low

Bout time for a new pump... News didn't help.  

ALLR, new 52 week low

No longer in but happy you made a great trade on it...🥳

ALLR $1,65 + 10%

2.25 on pump now back to 1.60s is a low floater Allarity Therapeutics to be Granted European Patent for DRP® Companion Diagnostic for Stenoparib

Source: GlobeNewswire Inc.

European Patent Office to grant a patent for DRP® companion diagnostic for Allarity’s stenoparib cancer therapy


Patent applications for the Stenoparib DRP® are also pending in the US, Japan, China, Australia, and India



Boston (October 22, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments using its proprietary, drug-specific patient selection technology, today announced that the European Patent Office (EPO) has issued a formal notice of its intention to grant a patent for Allarity’s Drug Response Predictor (DRP®) companion diagnostic specific to stenoparib, the Company’s dual-targeted PARP/Tankyrase inhibitor.

This patent represents a significant step forward in securing Allarity’s market position for stenoparib and the Stenoparib DRP companion diagnostic, which identifies patients most likely to derive clinical benefit from stenoparib treatment.

Thomas Jensen, CEO of Allarity Therapeutics, commented, “As we advance our clinical program for stenoparib, we are also focused on securing patents in key markets to pave the way for potential future commercialization. Though our main focus is to first achieve regulatory approval in the US for both stenoparib and its DRP companion diagnostic, we strongly believe stenoparib has the potential to help ovarian cancer patients worldwide. Therefore, knowing that the EPO intends to grant us a European patent for the Stenoparib DRP is an important step towards securing the foundation for an international market position for stenoparib and its companion diagnostic."

Patent applications for the Stenoparib DRP companion diagnostic are also pending in the United States, Japan, China, Australia, and India. Allarity has previously been granted 17 patents for drug-specific DRPs, including eight in the United States.



About Stenoparib
Stenoparib is an orally available, small-molecule, dual-targeted inhibitor of PARP1/2 and Tankyrase 1 and 2. At present, tankyrases are attracting significant attention as emerging therapeutic targets for cancer, principally due to their role in regulating the Wnt signaling pathway. Aberrant Wnt/ß-catenin signaling has been implicated in the development and progression of numerous cancers. By inhibiting PARP and also blocking Wnt pathway activation, stenoparib’s unique therapeutic action shows potential as a promising therapeutic. Allarity has exclusive global rights for the development and commercialization of stenoparib, which was originally developed by Eisai Co. Ltd. and was formerly known under the names E7449 and 2X-121.

About the Drug Response Predictor – DRP® Companion Diagnostic
Allarity uses its drug-specific DRP® to select those patients who, by the gene expression signature of their cancer, are found to have a high likelihood of benefiting from a specific drug. By screening patients before treatment, and only treating those patients with a sufficiently high, drug-specific DRP score, the therapeutic benefit rate may be significantly increased. The DRP method builds on the comparison of sensitive vs. resistant human cancer cell lines, including transcriptomic information from cell lines combined with clinical tumor biology filters and prior clinical trial outcomes. DRP is based on messenger RNA expression profiles from patient biopsies. The DRP® platform has proven its ability to provide a statistically significant prediction of the clinical outcome from drug treatment in cancer patients dozens of clinical studies (both retrospective and prospective). The DRP platform, which can be used in all cancer types and is patented for more than 70 anti-cancer drugs, has been extensively published in the peer-reviewed literature.

About Allarity Therapeutics

ALLR new 52 week low

ALLR new 52 week low

ALLR under $2

ALLR new 52 week low